Industry news that matters to you.  Learn more

Caris Life Sciences Launches Significant Enhancements to Industry-leading Cancer Tumor Profiling Service

Reading time: 2 – 3 minutes

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, recently launched significant enhancements to its Molecular Intelligence™ tumor profiling service. These enhancements include significant updates to MI Portal™, the company’s online physician resource, a streamlined molecular profiling panel structure and the addition of two biomarkers.

Revamped MI Portal™ – This newly upgraded interface enables a physician or other authorized medical staff to securely and conveniently order Molecular Intelligence™ services online, manage patient reports, create custom alerts to activate or complete a test and more.

Simplified profile structure – In response to physician feedback and ordering trends, Caris’ two existing molecular panels (formerly MI Profile™ and MI Profile™ PLUS) have been consolidated into one streamlined service, now simply called MI Profile™. This multi-platform, pan-tumor biomarker analysis for therapeutic decision support and clinical trials matching is particularly helpful when selecting optimal treatment for patients with rare tumors or difficult-to-treat, refractory disease.

GNAQ and IDH2 biomarkers added – As part of the company’s commitment to adding the most clinically relevant biomarker-to-drug associations to its tumor profiling service, Caris has added two new biomarkers – GNAQ mutation and IDH2 both assessed by sequencing.

“We have invested hundreds of millions of dollars to ensure cancer patients have access to the latest diagnostic tools to help give them the best possible chance to defeat their disease,” said David D. Halbert, Chairman and Chief Executive Officer at Caris Life Sciences. “We are unrelenting in our commitment to innovation. These newly announced enhancements further establish our position as the leader in comprehensive, clinically relevant tumor profiling.”

Caris Molecular Intelligence™ uses multiple evidence-guided profiling technologies — IHC, FISH/CISH, PCR and Next-Generation Sequencing – to provide oncologists with the most relevant, clinically actionable potential treatment information to help them personalize care for their patients. Unlike other commercially available tumor profiling services, Molecular Intelligence™ more completely interrogates a patient’s unique tumor biology, assessing additional important biological components like RNA and protein expression levels to help an oncologist develop an individualized treatment plan. For a complete list of assays and biomarkers included in the MI Profile panel, visit the MI Profile menu at www.CarisMolecularIntelligence.com/profilemenu.

Source: Caris Life Sciences